SOAN Liprostin™ 4x Faster than FDA Approved Cilostazol™
The SOAN (AngioSoma, Inc.) drug known as Liprostin™ works four times faster than an already FDA approved drug Cilostazol™ for treating intermittent claudication:
This PR below strongly suggests two things for me regarding SOAN; either the company is going to get bought out or they are going to get FDA Approval with their drug called Liprostin™ of which I will reflect more about the drug following this PR below:
As indicated above and underlined in green, SOAN is using a drug within its Liprostin™ drug that's in the queue for FDA Approval that is licensed by Pfizer that is already FDA Approved called Alprostadil which further leads me to think that FDA Approval for SOAN and its Liprostin™ is in the near future:
To further substantiate why I believe that either a buyout or an FDA Approval is in the near future for SOAN, take a look at their management team below and their credentials:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.